- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- MILs, Melphalan, PCV13
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 94
matching trials from the live ClinicalTrials.gov search.
- Conditions
- End Stage Renal Disease
- Interventions
- 13-valent conjugate pneumococcal vaccine
- Biological
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Lansing, Michigan
- Conditions
- Meningococcal Disease, Meningococcal Meningitis
- Interventions
- MenACWY-CRM, Routine Vaccines
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 55 Days to 89 Days
- Enrollment
- 751 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 30 more
- Conditions
- Healthy Subjects, Pneumococcal Infections
- Interventions
- 13-Valent Pneumococcal Conjugate Vaccine (13vPnC), 7-Valent Pneumococcal Conjugate Vaccine (7vPnC)
- Biological
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 42 Days to 98 Days
- Enrollment
- 249 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chickenpox
- Interventions
- Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Huntington Park, California + 18 more
- Conditions
- Pneumococcal Disease
- Interventions
- 20-valent pneumococcal conjugate vaccine, 13-valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 42 Days to 98 Days
- Enrollment
- 1,997 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 78 more
- Conditions
- Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation, Pertussis Immunisation, Hepatitis B Immunisation, Haemophilus Influenzae Type b Immunisation, Polio Immunisation, Measles Immunisation, Rubella Immunisation, Varicella Immunisation, Mumps Immunisation
- Interventions
- Pneumococcal Conjugate Vaccine formulation 1, Pneumococcal Conjugate Vaccine formulation 2, Pneumococcal Conjugate Vaccine formulation 3, Varicella Virus Vaccine Live, Measles, Mumps, and Rubella Virus Vaccine Live, Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein], Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate), Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine* [Recombinant] *as applicable
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 15 Months
- Enrollment
- 852 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 49
- States / cities
- Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more
- Conditions
- Pneumococcal Infection
- Interventions
- PNEUMOVAX, Prevnar
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 25 Years to 89 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Decatur, Georgia
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine, Therapeutic Autologous Dendritic Cells, Durvalumab, Esophagogastroduodenoscopy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biopsy Procedure, Biospecimen Collection
- Biological · Radiation · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Herpes Zoster
- Interventions
- HZ/su vaccine GSK1437173A, Prevenar13
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 913 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Marlborough, Massachusetts • Salisbury, North Carolina • Spartanburg, South Carolina
- Conditions
- Meningitis, Meningococcal Infection
- Interventions
- Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 42 Days to 365 Days
- Enrollment
- 580 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more
- Conditions
- Extraintestinal Pathogenic Escherichia Coli Prevention
- Interventions
- ExPEC10V, ExPEC4V, Prevnar 13, Placebo
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 836 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 12
- States / cities
- Huntsville, Alabama • Melbourne, Florida • Miami, Florida + 9 more
- Conditions
- Pneumococcal Conjugate Vaccine
- Interventions
- 13-valent Pneumococcal Conjugate Vaccine
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 8 Years to 16 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 2
- States / cities
- Hayward, California • San Jose, California
- Conditions
- Pneumococcal Infections, Pneumonia, Pneumococcal
- Interventions
- V114, Prevnar 13™
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 2,340 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 30
- States / cities
- Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more
- Conditions
- Meningitis, Meningococcal
- Interventions
- Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 2 Months to 2 Months
- Enrollment
- 4,545 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 53
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
- Conditions
- Haemophilus Influenzae Type b
- Interventions
- GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™, Pediarix™, Prevnar 13™, Rotarix™, Engerix™-B, Infanrix™
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 4,003 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 63
- States / cities
- Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more
- Conditions
- Pneumococcal Disease
- Interventions
- No Intervention
- Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Months to 3 Years
- Enrollment
- 53,902 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
- Interventions
- 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine, Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more
- Conditions
- Pneumococcal Immunization
- Interventions
- Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb, Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI, Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII, Pneumococcal 13 - valent conjugate vaccine-Prevnar 13, Pneumococcal Vaccine Polyvalent-Pneumovax 23
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years to 84 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 17
- States / cities
- Anaheim, California • Rolling Hills Estates, California • Wheat Ridge, Colorado + 14 more
- Conditions
- Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
- Interventions
- Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 1,742 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 69 more
- Conditions
- Fever After Vaccination, Fever, Febrile Seizure
- Interventions
- PCV13, DTaP, IIV
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 12 Months to 16 Months
- Enrollment
- 221 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Oakland, California • Atlanta, Georgia • Durham, North Carolina
- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 42 Days to 90 Days
- Enrollment
- 2,409 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 22
- States / cities
- Downey, California • Huntington Beach, California • San Diego, California + 18 more
- Conditions
- HIV, Pneumonia, Infections, Pneumococcal
- Interventions
- Vaccine Administration
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350,399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neisseria Meningitidis, Haemophilus Influenzae Type b
- Interventions
- Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix®, Prevnar 13®, PedvaxHIB®, Havrix®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 23 more